Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Castle Biosciences, Inc.

< Previous 1 2 3 4 5 Next >
Castle Biosciences Reports Second Quarter 2025 Results
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
Castle Biosciences Celebrates Skin Cancer Awareness Month
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
Castle Biosciences Reports First Quarter 2025 Results
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
Castle Biosciences to Acquire Previse
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups
From Castle Biosciences, Inc.
Via GlobeNewswire
Tickers CSTL
Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Real-World Evidence Confirms IDgenetix®-Guided Medication Management Significantly Improves Response and Remission Rates in Patients with Major Depressive Disorder
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept. 27, 2023, to Raise Awareness of Melanoma
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Host Second Annual Castle Cares Charity Walk
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.